natgillin/translations-raw huggingface dataset:
CNS 7056 or the salt or solvate thereof for use according claim 2, characterised in that the initial dose and the top-up doses of CNS 7056 are combined as follows: 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevu 2, naznačen time što se inicijalna doza i dopunske doze CNS 7056 kombiniraju kako slijedi:
CNS 7056 or the salt or solvate thereof for use according to claim 2 to 4, characterised in that not more than six top-up doses of CNS 7056 are given. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevu 2 do 4, naznačen time što se ne daje više od šest dopunskih doza CNS 7056.
CNS 7056 or the salt or solvate thereof for use according to any of the preceding claims, characterised in that the fentanyl is given before administration of CNS 7056, preferably within 10 minutes, more preferably within 5 minutes, and most preferably within 1 or 2 minutes prior to CNS 7056 administration. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno bilo kojem od prethodnih zahtjeva, naznačen time što se fentanil daje prije davanja CNS 7056, a prvenstveno u roku od 10 minuta, još poželjnije u roku od 5 minuta, i najpoželjnije u roku od 1 ili 2 minuta prije davanja CNS 7056.
CNS 7056 or the salt or solvate thereof for use according to claim 7, characterised in that a top-up dose of fentanyl is administered not earlier than 5 minutes after the precedent fentanyl dose. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevu 7, naznačen time što se dopunska doza fentanila ne daje ranije od 5 minuta nakon prethodne doze fentanila.
CNS 7056 or the salt or solvate thereof for use according to any of claims 1 to 5 and 8, characterised in that the maximum dose of fentanyl per treatment does not exceed 200 mcg/patient. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno bilo kojem od zahtjeva 1 do 5 i 8, naznačen time što maksimalna doza fentanila po tretmanu ne prelazi 200 mcg/pacijentu.
CNS 7056 or the salt or solvate thereof for use according to claims 1 to 8, characterised in that the sedation is induced within a procedural sedation, preferably for the performance of an endoscopy, more preferably of an upper GI endoscopy or colonoscopy. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevima 1 do 8, naznačen time što se sediranje inducira u okviru proceduralnog sediranja, a prvenstveno radi provođenja endoskopije, još poželjnije endoskopije gornjeg GI ili kolonoskopije.
CNS 7056 or the salt or solvate thereof for use according to any of the above claims, which is in the form of a container for pharmaceutical use comprising 10 mg of CNS7056 or the salt or solvate thereof, preferably in a concentration of 1 mg/ml. 
CNS 7056 ili njegova sol ili solvat radi primjene sukladno bilo kojem od gornjih zahtjeva, koji je u obliku spremnika za farmaceutsku uporabu koji sadrži 10 mg CNS7056 ili njegove soli ili solvata, a prvenstveno u koncentraciji od 1 mg/ml.
CNS 7056 or the salt or solvate thereof for use according to claim 14, wherein the container constitutes a drug product, preferably a ready-to-use drug product. 
CNS 7056 ili njegova sol ili solvat radi primjene sukladno zahtjevu 14, pri čemu spremnik predstavlja farmaceutski proizvod, a prvenstveno farmaceutski proizvod spreman za uporabu.
A formulation for personal hygiene in the form of O/W emulsion with a pH from 5.5 to 6.5, free of surfactants except for comprising an emulsifier consisting of a fatty alcohol having from 14 to 22 carbon atoms or of Glyceryl Stearate or a mixture thereof, which formulation further comprises Coco Caprylate and/or Coco Caprylate/Caprate, vitamin E or an ester thereof in an amount of 2.0 to 15% by weight on the total weight of the formulation, and Melaleuca alternifolia oil. 
Formulacija za osobnu higijenu u obliku ulje/voda emulzije s pH od 5.5 do 6.5, bez surfaktanata osim što sadrži emulgator koji se sastoji od masnog alkohola koji ima 14 do 22 atoma ugljika ili gliceril stearata ili njihove smjese, pri čemu ta formulacija dalje sadrži koko kaprilat i/ili koko kaprilat/kaprat, vitamin E ili njegov ester u količini od 2.0 do 15 težinskih % na ukupnu težinu formulacije i ulje Melaleuca alternifolia.
The formulation according to claim 1, wherein said fatty alcohol is selected from the group consisting of lauryl alcohol, stearyl alcohol, myristyl alcohol, arachidyl alcohol, behenyl alcohol and cetylstearyl alcohol and is preferably cetylstearyl alcohol (Cetearyl Alcohol). 
Formulacija prema patentnom zahtjevu 1, naznačen time što je navedeni masni alkohol izabran iz grupe koja se sastoji od lauril alkohola, stearil alkohola, miristil alkohola, arahidil alkohola, behenil alkohola i cetilstearil alkohola i poželjno je cetilstearil alkohol (cetearil alkohol).
The formulation according to any one of the preceding claims, further comprising jojoba oil (Simmondsia Chinensis Oil) and/or shea butter (Butyrospermum Parkii Butter). 
Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, koja dalje sadrži ulje jojobe (ulje Simmondsia chinensis) i/ili shea maslac (maslac Butyrospermum parkii).
The formulation according to any one of the preceding claims further comprising an organic acid selected from lactic, malic, citric and acetic acid, preferably lactic acid. 
Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, koja dalje sadrži organsku kiselinu izabranu od mliječne, jabučne, limunske i octene kiseline, poželjno mliječne kiseline.
The formulation according to claim 1, containing the following ingredients, in percentages by weight on the total weight of the formulation: 
Formulacija prema patentnom zahtjevu 1, koja sadrži sljedeće sastojke, u težinskim postocima na ukupnu težinu formulacije:
The formulation according to claim 8, further containing 0.5-2.0% of jojoba oil (Simmondsia Chinensis Oil) and/or 3.0-8.0% of shea butter (Butyrospermum Parkii Butter). 
Formulacija prema patentnom zahtjevu 8, koja dalje sadrži 0.5-2.0% ulja jojobe (ulje Simmondsia chinensis) i/ili 3.0-8.0% shea maslaca (maslac Butyrospermum parkii).
is independently selected from: 
je neovisno odabran od:
and R2 are not simultaneously H, and 
i R2 nisu istovremeno H i
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to any one of claims 1-13. 
Farmaceutski pripravak, naznačen time, da sadrži farmaceutski prihvatljiv nosač i farmaceutski učinkovitu količinu spoja u skladu s bilo kojim od patentnih zahtjeva 1-13.
The pharmaceutical composition according to claim 15, wherein the further therapeutic agent is an agent for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 15, naznačen time, da je daljnje terapijsko sredstvo sredstvo za profilaksu i/ili liječenje upalnih stanja i/ili poremećaja koje uključuju degradaciju hrskavice i/ili poremećaj homeostaze hrskavice.
wherein at least 95% of the anti-FGFR2IIIb antibodies in the composition are afucosylated; 
pri čemu je najmanje 95 % anti-FGFR2IIIb protutijela u pripravku afukozilirana;
for use in a method of treatment of cancer in an individual, wherein the cancer overexpresses FGFR2IIIb. 
naznačen time što je za upotrebu u postupku liječenja raka kod pojedinca, pri čemu rak prekomjerno eksprimira FGFR2IIIb.
The composition for use according to claim 1 or 2, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:2, or wherein the light chain comprises the amino acid sequence of SEQ ID NO:3, or both. 
Pripravak za uporabu prema zahtjevu 1 ili 2, naznačen time što teški lanac sadrži sekvencu aminokiseline SEQ ID NO:2, ili pri čemu lagani lanac sadrži sekvencu aminokiseline SEQ ID NO:3, ili oboje.
The composition for use according to any one of claims 1 to 5, wherein the afucosylated antibodies have enhanced ADCC activity in vitro compared to a fucosylated anti-FGFR2IIIb antibody having the same amino acid sequence; and/or wherein the afucosylated antibodies have enhanced affinity for Fc gamma RIIIA compared to a fucosylated anti-FGFR2IIIb antibody having the same amino acid sequence. 
Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time što afukozilirana protutijela imaju poboljšanu in vitro ADCC aktivnost u usporedbi s fukoziliranim anti-FGFR2IIIb protutijelom koje ima istu sekvencu aminokiseline; i/ili pri čemu afukozilirana protutijela imaju povećani afinitet za Fc gama RIIIA u usporedbi s fukoziliranim anti-FGFR2IIIb protutijelom koje ima istu sekvencu aminokiseline.
The composition for use according to claim 6, wherein the afucosylated antibodies have enhanced affinity for Fc gamma RIIIA compared to a fucosylated anti-FGFR2IIIb antibody having the same amino acid sequence and the Fc gamma RIIIA is selected from Fc gamma RIIIA(V158) and Fc gamma RIIIA(F158). 
Pripravak za uporabu prema zahtjevu 6, naznačen time što afukozilirana protutijela imaju povećani afinitet za Fc gama RIIIA u usporedbi s fukoziliranim anti-FGFR2IIIb protutijelom koje ima istu sekvencu aminokiseline i Fc gama RIIIA se bira od Fc gama RIIIA (V158) i Fc gama RIIIA (F158).
The composition for use according to any one of claims 1 to 13, wherein the treatment further comprises administering at least one additional therapeutic agent selected from a platinum agent, paclitaxel, ABRAXANE®, docetaxel, gemcitabine, capecitabine, irinotecan, epirubicin, FOLFOX, FOLFIRI, leucovorin, fluorouracil, mitomycin C, and doxorubicin hydrochloride. 
Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 13, naznačen time što liječenje nadalje obuhvaća primjenu najmanje jednog dodatnog terapijskog sredstva odabranog od sredstva na bazi platine, paklitaksela, ABRAXANE®, docetaksela, gemcitabina, kapecitabina, irinotekana, epirubicina, FOLFOX, FOLFIRI, leukovorina, fluorouracila, mitomicina C i doksorubicin hidroklorida.
The composition for use according to claim 14, wherein the platinum agent is selected from cisplatin, oxaliplatin, and carboplatin, or the additional agent is cisplatin and/or 5-flurouracil. 
Pripravak za uporabu prema zahtjevu 14, naznačen time što je sredstvo na bazi platine odabrano od cisplatina, oksaliplatina i karboplatina ili je dodatno sredstvo cisplatin i/ili 5-flurouracil.
HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11, for use in a method of treatment of cancer in an individual, wherein the cancer overexpresses FGFR2IIIb. 
HVR-L3 koji sadrži sekvencu aminokiseline SEQ ID NO: 11, naznačeno time što je za uporabu u postupku liječenja raka kod pojedinca, pri čemu rak prekomjerno eksprimira FGFR2IIIb.
The antibody for use according to claim 16 or 17, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:2, or wherein the light chain comprises the amino acid sequence of SEQ ID NO:3, or both. 
Protutijelo za uporabu prema zahtjevu 16 ili 17, naznačeno time što teški lanac sadrži sekvencu aminokiseline SEQ ID NO:2, ili pri čemu lagani lanac sadrži sekvencu aminokiseline SEQ ID NO:3, ili oboje.
A pharmaceutical composition consisting of: 
Farmaceutski pripravak koji se sastoji od:
A composition according to claim 1 for use in the treatment of a skin disorder. 
Pripravak prema patentnom zahtjevu 1 za upotrebu u liječenju poremećaja kože.
a 2nd holding unit for holding an aqueous solution comprising a drug; 
drugu jedinicu za držanje vodene otopine koja sadrži terapeutski lijek;
an injection means configured to add the organic lipid solution from the 1st holding unit to the aqueous drug solution contained in the mixing unit to form a gradient of the organic solvent concentration of the solution in the mixing unit from an injection-initial value to injection-final value; 
sredstva za injektiranje za dodavanje otopine organskih lipida iz prve jedinice za držanje u komoru za miješanje na način da nastaje gradijent koncentracije organskog otapala za otopinu u jedinici za miješanje tako da je povećanje postupno od početne vrijednosti injektiranja do konačne vrijednosti injektiranja;
a 3rd holding unit for holding an aqueous buffer; 
treću jedinicu za držanje za vodeni pufer;
A process for the preparation of a compound of formula (I-E) 
Postupak za pripravu spoja s formulom (I-E) pri čemu
A process as in claim 1, wherein R1 is cyclobutyl; R2 is Z—Ar, wherein Ar is selected from the group consisting of 4-fluorophenyl, 3-cyanophenyl, and 4-tetrahydropyranyl; LG1 is chloro; and LG2 is chloro. 
Postupak prema zahtjevu 1, naznačen time da je R1 ciklobutil, m je 2 i R2 je odabran iz skupine koja se sastoji od 4-fluorofenila, 3-cijanofenila, 4-tetrahidropiranila, LG1 je kloro i LG2 je kloro.
The composition of claim 1, wherein the supernatant of the M.hyo culture has been treated with protein-A or protein-G prior to being added to the immunogenic composition. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je supernatant kulture M.hyo obrađen proteinom-A ili proteinom-G prije dodavanja imunogenom pripravku.
The composition for the use of claim 9 or 10, wherein the composition is administered to pigs having maternally derived antibodies against at least one of M.hyo, PCV2, and PRRS virus. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 9 ili 10, naznačen time što se pripravak primjenjuje na prasadi koja sadrži protutijela majčinskog podrijetla protiv najmanje jednog od M.hyo, PCV2, te virusa PRRS.
A kit comprising an immunogenic or vaccine composition as defined in any of claims 1 to 14, wherein a first bottle comprises both a PCV2 antigen and the supernatant of a Mycoplasma hyopneumoniae (M.hyo) culture, wherein the supernatant is free of both (i) IgG and (ii) antigen/immunoglobulin immunocomplexes, and a second bottle comprises PRRS virus antigen; and optionally, further including an instruction manual with directions to combine the contents of the first bottle with the contents of the second bottle and to administer the combined contents of the first and second bottles to a pig. 
Komplet, naznačen time što sadrži imunogeni ili cjepivni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 14, gdje prva boca sadrži i antigen iz PCV2 i supernatant kulture bakterije Mycoplasma hyopneumoniae (M.hyo), gdje supernatant ne sadrži ni (i) IgG niti (ii) imunokomplekse antigen/imunoglobulin, a druga boca sadrži antigen virusa PRRS; i izborno može sadržavati priručnik s uputama i preporukama o kombiniranju sadržaja prve boce sa sadržajem druge boce i primjeni kombiniranih sadržaja prve i druge boce na prasetu.
culturing M.hyo in a suitable media over periods ranging from 18-144 hours; 
uzgoju M.hyo u pogodnim medijima u periodima koji se kreću od 18-144 sati;
iii) harvesting the inactivated culture fluid, wherein the inactivated culture fluid comprises both a soluble liquid fraction and insoluble cellular material; 
iii) prikupljanju fluida od inaktivirane kulture, gdje fluid od inaktivirane kulture sadrži i topljivu tekuću frakciju i netopljivi stanični materijal;
iv) separating the soluble liquid fraction from the insoluble cellular material by filtration, centrifugation or precipitation; 
iv) odvajenju topljive tekuće frakcije od netopljivog staničnog materijala filtriranjem, centrifugiranjem ili taloženjem;
The antibody molecule for use of claim 1, wherein said antibody molecule is a humanized antibody molecule, and/or a monospecific antibody molecule or a bispecific antibody molecule. 
Molekula protutijela sukladno patentnom zahtjevu 1, naznačen time što navedena molekula protutijela je humanizirana molekula protutijela i/ili monospecifični molekula protutijela ili bispecifična molekula protutijela .
a heavy chain variable region comprising at least one, two, three or four framework (FW) regions comprising the amino acid sequence of any of SEQ ID NOs: 147, 151, 153, 157, 160, 162, 166, or 169, or an amino acid sequence at least 90% identical thereto, or having no more than two amino acid substitutions, insertions or deletions compared to the amino acid sequence of any of SEQ ID NOs: 147, 151, 153, 157, 160, 162, 166, or 169; and/or a light chain variable region comprising at least one, two, three or four framework regions comprising the amino acid sequence of any of SEQ ID NOs: 174, 177, 181, 183, 185, 187, 191, 194, 196, 200, 202, 205, or 208, or an amino acid sequence at least 90% identical thereto, or having no more than two amino acid substitutions, insertions or deletions compared to the amino acid sequence of any of 174, 177, 181, 183, 185, 187, 191, 194, 196, 200, 202, 205, or 208. 
promjenjiva regija teškog lanca koji sadrži najmanje jednu, dvije, tri ili četiri okvirne (FW) regije koja sadrže aminokiselinsku sekvencu sukladno bilo kojoj od SEQ ID NOs: 147, 151, 153, 157, 160, 162, 166 ili 169, ili aminokiselinsku sekvencu koja joj je najmanje 90% jednaka ili koja ima ne više od dve aminokiselinske supstitucije, insercije ili delecije u usporedbi s aminokiselinskom sekvencom sukladno bilo kojoj od SEQ ID NOs: 147, 151, 153, 157, 160, 162, 166 ili 169; i/ili promjenjiva regija lakog lanca koji sadrži najmanje jednu, dvije, tri ili četiri okvirne regije koja sadri aminokiselinsku sekvencu sukladno bilo kojoj od SEQ ID NOs: 174, 177, 181, 183, 185, 187, 191, 194, 196, 200, 202, 205 ili 208, ili aminokiselinsku sekvencu koja joj je najmanje 90% jednaka, ili koja ima ne više od dvije aminokiselinske supstitucije, insercije ili delecije u usporedbi s aminokiselinskom sekvencom sukladno bilo kojoj od 174, 177, 181, 183, 185, 187, 191, 194, 196, 200, 202, 205 ili 208.
is capable of binding to human PD-1 with a dissociation constant (KD) of less than about 0.2 nM; 
je sposoban vezati se za humani PD-1 s konstantnom disocijacije (KD) od manje od oko 0.2 nM;
binds an extracellular Ig-like domain of PD-1; is capable of reducing binding of PD-1 to PD-L1, PD-L2, or both, or a cell that expresses PD-L1, PD-L2, or both; and/or 
se veže za ekstracelularnu domenu PD-1 sličnu Ig1; i/ili je sposoban da smanji vezivanje PD-1 za PD-L1 i PD-L2 ili za stanicu koja eksprimira PD-L1 i PD-L2.
A pharmaceutical composition comprising the antibody molecule, MEK inhibitor and/or a BRAF inhibitor of any of claims 1-12 and a pharmaceutically acceptable carrier, excipient or stabilizer. 
Farmaceutska kompozicija koja sadrži molekulu protutijela sukladno bilo kojem od patentnih zahtjeva 1-12 i farmaceutski prihvatljiv nosač, ekscipijens ili stabilizator.
An antibody molecule for use of any of claims 1-13, or a pharmaceutical composition of claim 14, for use in a method of stimulating an immune response or treating a cancer or an infectious disease in a subject. 
Molekula protutijela sukladno bilo kojem od patentnih zahtjeva 1-12, ili farmaceutski pripravak sukladno patentnom zahtjevu 13, za uporabu u postupku stimulacije imunološkog odgovora ili liječenja karcinoma ili infektivne bolesti kod subjekta.
a cancer that is triple positive for PD-L1, CD8 and IFN-γ; or 
karcinoma koji je trostruko pozitivan za PD-L1, CD8 i IFN-γ; ili
The pharmaceutical combination of Claim 30 wherein the second compound is selected from the group consisting of a corticosteroid, hydroxychloroquine, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, janus kinase inhibitor, statin, calcipotriene, angiotensin-converting enzyme inhibitor and angiotensin receptor blocker; and an optional pharmaceutically acceptable carrier, excipient or diluents. 
drugi spoj, gdje se drugi spoj bira iz skupine koju čine kortikosteroid, hidroksiklorokin, ciklofosfamid, azatioprin, mikofenolat mofetil, metotreksat, inhibitor janus kinaze, statin, kalcipotrien, inhibitor angiotenzin-konvertirajućeg enzima i blokator angiotenzinskog receptora; i izborna farmaceutski prihvatljiva podloga, pomoćna tvar ili razrjeđivači.
PM01183, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, comprising administering a therapeutically effective amount of PM01183, or a pharmaceutically acceptable salt thereof, in synergistic combination with a therapeutically effective amount of an antimetabolite, wherein the antimetabolite is selected from 5-fluorouracil, gemcitabine, cytarabine, capecitabine, decitabine, floxuridine, aminopterin, methotrexate, pemetrexed and raltitrexed. 
PM01183, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju raka, koja se sastoji u primjeni terapijski djelotvorne količine PM01183, ili njegove farmaceutski prihvatljive soli, u sinergističkoj kombinaciji s terapijski djelotvornom količinom inhibitora mitoze, gdje se inhibitor mitoze bira između paklitaksela, docetaksela, vinkristina i vinorelbina.
PM01183, or a pharmaceutically acceptable salt thereof, for use according to claim 8, wherein the cancer to be treated is selected from lung cancer, sarcoma, malignant melanoma, prostate cancer, pancreas carcinoma, gastric carcinoma, ovarian cancer, hepatoma, breast cancer, colorectal cancer, kidney cancer, brain cancer, leukemia and lymphoma. 
PM01183, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što se rak kojeg treba liječiti bira između raka pluća, sarkoma, raka prostate, karcinoma želuca, raka jajnika, hepatoma, raka dojke, kolorektalnog raka, raka bubrega, raka na mozgu.
The smoke evacuator or fire shutter according to claim 1, wherein said battery connector is designed to contact a battery yet not fix said battery in connection with said battery connector. 
Evakuator dima ili protupožarni kapak prema zahtjevu 1, pri čemu je gore navedeni priključak dizajniran za spajanje baterije u strujni krug, ali ne i za njezino fiksiranje ili učvršćivanje.
The smoke evacuator or fire shutter according to claim 1, wherein said housing is made air and dust tight. 
Evakuator dima ili protupožarni kapak prema zahtjevu 1, pri čemu je kućište hermetički zatvoreno.
The pharmaceutical composition of claim 1, wherein (a) 25% of the FVIII of the chimeric polypeptide is single chain FVIII and 75% of the FVIII of the chimeric polypeptide is processed FVIII, (b) 20% of the FVIII of the chimeric polypeptide is single chain FVIII and 80% of the FVIII of the chimeric polypeptide is processed FVIII, or (c) 15% of the FVIII of the chimeric polypeptide is single chain FVIII and 85% of the FVIII of the chimeric polypeptide is processed FVIII. 
Farmaceutski pripravak prema zahtjevu 1, naznačen time što (a) 25% FVIII dijela kimernog polipeptida je jednolančani FVIII i 75% FVIII dijela kimernog polipeptida je obrađeni FVIII, (b) 20% FVIII dijela kimernog polipeptida je jednolančani FVIII i 80% FVIII dijela kimernog polipeptida je obrađeni FVIII, ili (c) 15% FVIII dijela kimernog polipeptida je jednolančani FVIII i 85% FVIII dijela kimernog polipeptida je obrađeni FVIII.
The pharmaceutical composition of claim 1, wherein the second portion is selected from the group consisting of an Fc region, albumin, a PAS sequence, transferrin, CTP (28 amino acid C-terminal peptide (CTP) of hCG with its 4 O-glycans), polyethylene glycol (PEG), hydroxyethyl starch (HES), albumin binding polypeptide, albumin-binding small molecules, and two or more combinations thereof. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time što drugi dio obuhvaća Fc regiju, albumin, PAS sekvencu, transferin, CTP (C-terminalni peptid od 28 aminokiselina (CTP) od hCG sa 4O-glikanima), polietilen glikol (PEG), hidroksietil škrob (HES), albumin vezujući polipeptid, male molekule koje vežu albumin, ili dvije ili više njihovih kombinacija.
A tablet comprising up to 5 mg apixaban and a pharmaceutically acceptable diluent or carrier, wherein the tablet is obtainable by a process comprising the steps of: 
Tableta koja sadrži do 5 mg apiksabana i farmaceutski prihvatljivo otapalo ili nosač, gdje je tabletu moguće dobiti pomoću procesa koji obuhvaća korake:
granulating the raw materials from the step (1) using a dry granulation process, wherein the crystalline apixaban particles have a D90 less than 89 µm, as measured by laser light scattering; 
granulacije sirovih materijala iz koraka (1) primjenom procesa suhe granulacije, pri čemu čestice kristalnog apiksabana imaju D90 manji od 89 µm, kao što je mjereno laserskim raspršivanjem svjetlosti;